Press Releases
FDA Approves IsoPSA® -- Cleveland Diagnostics’ Novel Blood-Based Prostate Cancer Test
READ MORE
12.1.25
08.27.25
Cleveland Diagnostics Brings PSA on PSA Campaign Back This September
READ MORE
04.23.25
Cleveland Diagnostics Announces Landmark Longitudinal Study Published in Urology
READ MORE
Cleveland Diagnostics’ Prostate Cancer Awareness Campaign ‘A PSA on PSA’ Returns This September
READ MORE
08.27.24
Cleveland Diagnostics Adds Dara Grantham Wright to Board of Directors
READ MORE
07.23.24
Cleveland Diagnostics Completes $75M Financing to Advance its Early-detection Oncology Testing Platform
READ MORE
1.17.24
Cleveland Diagnostics Announces Prostate Cancer Awareness Month Campaign: ‘A PSA on PSA’
READ MORE
8.30.23
Cleveland Diagnostics Opens New Facility Amid Growing Demand for IsoPSA® Test
READ MORE
6.28.23
Cleveland Diagnostics Announces Agreement with Quest Diagnostics to Expand Patient Access to IsoPSA® Prostate Cancer Testing
READ MORE
2.13.23
Cleveland Diagnostics Announces the Publication of Two Major IsoPSA® Studies
READ MORE
10.31.22
Cleveland Diagnostics Announces Favorable Medicare Local Coverage Determination and Assignment of a CPT-PLA Code for IsoPSA®
READ MORE
10.13.22
Cleveland Diagnostics Announces Inclusion of IsoPSA® in National Comprehensive Cancer Network® Guidelines for Prostate Cancer Early Detection
READ MORE
5.11.22
Cleveland Diagnostics Announces Publication of Real-World Study Demonstrating the Clinical Utility of IsoPSA® for Prostate Cancer Risk Assessment
READ MORE
2.23.22
Cleveland Diagnostics Presents New Data Supporting the Clinical Validation and Clinical Utility of IsoPSA at the 2021 Annual Meeting of American Urological Association
READ MORE
9.14.21
Cleveland Diagnostics Receives College of American Pathologists (CAP) Accreditation for Its Clinical Laboratory
READ MORE